Each year, approximately 177,000 adults aged 65 and older are hospitalized in the United States due to RSV, and an estimated ...

A study by former Junior Associate Professor Kazuo Takayama, currently a professor of the Institute of Science Tokyo, ...

A single-dose of the respiratory syncytial virus (RSV) vaccine in older adults showed waning efficacy across three seasons of ...

EPS estimates, maintains 2025 guidance, and targets $5.7 billion in cost savings through automation and R&D streamlining.

Researchers from GlaxoSmithKline have reported that a single dose of the RSV vaccine, Arexvy (RSVPreF3 OA), provides ...

A federal panel of experts on Wednesday recommended an expansion of RSV vaccinations for adults and a new combination shot as ...

The seasonal timing of when infants receive the new respiratory syncytial virus (RSV) immunization is crucial for ensuring ...

The British pharmaceutical giant said that its first-quarter sales rose to 7.52 billion pounds from 7.36 billion pounds the ...

Brazil is experiencing an increase in Severe Acute Respiratory Syndrome (SARS) cases, with 13 states and the Federal District ...

Ziresovir is the first antiviral to demonstrate significant clinical efficacy and long-term respiratory benefits in ...

A  scientific forum held in HCM City on April 27 announced a pioneering preventive method to help prevent lower respiratory ...